Illumina, Inc. $ILMN Shares Sold by Kids Capital Management L.P.

Kids Capital Management L.P. reduced its holdings in Illumina, Inc. (NASDAQ:ILMN) by 12.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 88,000 shares of the life sciences company’s stock after selling 12,000 shares during the quarter. Illumina comprises approximately 8.6% of Kids Capital Management L.P.’s investment portfolio, making the stock its 6th biggest holding. Kids Capital Management L.P.’s holdings in Illumina were worth $11,542,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its stake in Illumina by 17.5% in the third quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock valued at $79,081,000 after purchasing an additional 124,246 shares during the last quarter. Elo Mutual Pension Insurance Co acquired a new position in Illumina in the third quarter valued at $2,319,000. Caprock Group LLC acquired a new position in Illumina in the third quarter valued at $1,479,000. Capital World Investors increased its stake in Illumina by 20.0% in the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after purchasing an additional 3,331,542 shares during the last quarter. Finally, Nordea Investment Management AB increased its stake in Illumina by 2,792.2% in the fourth quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after purchasing an additional 911,843 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $160.97 on Friday. The firm has a market capitalization of $24.35 billion, a PE ratio of 29.27, a P/E/G ratio of 3.02 and a beta of 1.50. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The business has a 50-day moving average of $141.65 and a two-hundred day moving average of $134.99. Illumina, Inc. has a 12 month low of $85.77 and a 12 month high of $177.22.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, research analysts forecast that Illumina, Inc. will post 5.21 earnings per share for the current year.

Insider Activity at Illumina

In other Illumina news, Director Keith A. Meister sold 235,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the completion of the sale, the director directly owned 2,830,452 shares in the company, valued at $463,146,860.76. This represents a 7.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $98,400.00. Following the sale, the insider owned 21,568 shares of the company’s stock, valued at $3,450,880. This represents a 2.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,003,154 shares of company stock valued at $155,600,208 over the last three months. Insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Barclays upped their target price on Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research note on Friday, May 1st. Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. JPMorgan Chase & Co. upgraded Illumina from a “neutral” rating to an “overweight” rating and upped their target price for the company from $125.00 to $185.00 in a research note on Wednesday. Finally, Royal Bank Of Canada began coverage on Illumina in a research note on Thursday, May 14th. They issued an “outperform” rating and a $170.00 target price for the company. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Illumina has an average rating of “Hold” and a consensus target price of $142.13.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.